460470.KQ
IVIM Technology
KOE · Healthcare · Medical - Specialties · KR
KRW 2,730.00
−3.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.6B | 4.4B | 3.6B | 4.5B | 1.3B |
| Cost of Revenue | 5.2B | 3.1B | 2.2B | 3.1B | 1.2B |
| Gross Profit | 1.4B | 1.2B | 1.3B | 1.4B | 159.6M |
| Operating Expenses | |||||
| R&D Expense | 537.4M | 693.1M | 704.3M | 261.8M | 567.7M |
| SG&A Expense | 3.0B | 1.3B | 1.6B | 1.4B | 908.3M |
| General & Admin Expense | 429.0M | 546.7M | 653.2M | 580.0M | 415.4M |
| Selling & Marketing Expense | 610.8M | 762.6M | 955.2M | 799.4M | 492.9M |
| Other Expenses | 2.1B | 3.4B | 3.3B | 2.7B | 2.0B |
| Total Operating Expenses | 4.6B | 5.4B | 5.7B | 4.3B | 3.5B |
| Cost and Expenses | 9.8B | 8.5B | 7.9B | 7.4B | 4.7B |
| Operating Income (EBIT) | (3.2B) | (4.2B) | (4.3B) | (2.9B) | (3.3B) |
| Non-Operating | |||||
| Interest Income | 407.8M | 535.3M | 407.4M | 282.8M | 212.8M |
| Interest Expense | 137.9M | 160.6M | 184.5M | 1.6B | 2.1B |
| Net Interest Income | 269.9M | 374.7M | 223.0M | (502.1M) | (1.9B) |
| Other Non-Op Income/Expense | 516.7M | 350.4M | 306.1M | (2.1B) | (6.4B) |
| Non-Operating Income (excl Interest) | (316.0M) | — | (490.5M) | 532.0M | 4.3B |
| EBT (Pre-Tax Income) | (2.7B) | (3.8B) | (4.0B) | (5.0B) | (9.7B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (2.7B) | (3.8B) | (4.0B) | (5.0B) | (9.7B) |
| Earnings from Cont. Ops | (2.7B) | (3.8B) | (4.0B) | (5.0B) | (9.7B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.7B) | (3.8B) | (4.0B) | (5.0B) | (9.7B) |
| Per Share | |||||
| Basic EPS | (₩178) | (₩252) | (₩280) | (₩660) | (₩1,947) |
| Diluted EPS | (₩178) | (₩252) | (₩280) | (₩660) | (₩1,947) |
| Revenue Per Share | ₩434 | ₩290 | ₩249 | ₩588 | ₩268 |
| Shares | |||||
| Basic Shares Outstanding | 15.1M | 15.1M | 14.3M | 7.6M | 5.0M |
| Diluted Shares Outstanding | 15.1M | 15.1M | 14.3M | 7.6M | 5.0M |
| Profitability Metrics | |||||
| EBITDA | (1.6B) | (2.3B) | (2.4B) | (2.3B) | (6.8B) |
| D&A | 2.0B | 1.9B | 1.4B | 1.1B | 862.9M |
| EBIT | (3.0B) | (4.2B) | (3.8B) | (3.4B) | (7.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026